

BILL NUMBER: HB 869				DA 2/2	TE: 28/2023
COMMITTEE: Veterans					
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO	FOR	INFORMATIO	ONAL PURPOSES
		WITNESS NAME			
INDIVIDUAL:					
WITNESS NAME: APRIL HATCH			PF	IONE NUMBER:	
BUSINESS/ORGANIZATIC	DN NAME:		TI	TLE:	
ADDRESS:					
CITY:			ST	ATE:	ZIP:
EMAIL:		ATTENDANCE:		SUBMIT DATE: 2/28/2023 1	2:00 AM
THE INFORMA	TION ON THIS FORM	M IS PUBLIC RECOR	D UNDE		ER 610, RSMo.



BILL NUMBER: HB 869				DATE: 2/28/2023
COMMITTEE: Veterans				
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
INDIVIDUAL:				
WITNESS NAME: ARNIE C"HONEST	-ABE" DIENOFF-STAT	E PUBLIC ADVOCATE	PHONE NUME	BER:
BUSINESS/ORGANIZATIO	DN NAME:		TITLE:	
ADDRESS:			·	
CITY:			STATE:	ZIP:
EMAIL: arniedienoff@yah	oo.com	ATTENDANCE: Written	SUBMIT E 2/28/20	DATE: 23 11:27 PM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.
I am in Support of	this Bill with the use a	nd possibilities of Natura	al Remedies. This	is the first-step over

I am in Support of this Bill with the use and possibilities of Natural Remedies. This is the first-step over medicines and chemicals. I believe in Natural Medicine.



BILL NUMBER: HB 869				DA 2/2	TE: 28/2023
COMMITTEE: Veterans				·	
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO	FOR	INFORMATIC	ONAL PURPOSES
		WITNESS NAME			
INDIVIDUAL:					
WITNESS NAME: CARL SHEPARD			PH	HONE NUMBER:	
BUSINESS/ORGANIZATIC	NNAME:		TI.	TLE:	
ADDRESS:					
CITY:			ST	TATE:	ZIP:
EMAIL:		ATTENDANCE:		SUBMIT DATE: 2/28/2023 1	2:00 AM
THE INFORMA	TION ON THIS FORM		D UNDE	R CHAPTE	ER 610, RSMo.



BILL NUMBER: HB 869				DATE: 2/28/2023
COMMITTEE: Veterans				
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
	OBBYIST:			
WITNESS NAME: CHRISTOPHER HA	AMMANN		PHONE NUME 573-619-0	
REPRESENTING: GREAT STATE ST	RATEGIES		TITLE:	
ADDRESS:				
CITY: KANSAS CITY			STATE: MO	ZIP:
EMAIL:		ATTENDANCE:	SUBMIT I 2/28/20	DATE: 123 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.



BILL NUMBER: HB 869					TE: 28/2023
COMMITTEE: Veterans					
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO	FOR	INFORMATIO	ONAL PURPOSES
		WITNESS NAME			
INDIVIDUAL:					
WITNESS NAME: DANIEL HARKINS			PH	IONE NUMBER:	
BUSINESS/ORGANIZATIO	N NAME:		TI	TLE:	
ADDRESS:			ľ		
CITY:			ST	ATE:	ZIP:
EMAIL:		ATTENDANCE:		SUBMIT DATE: 2/28/2023	12:00 AM
THE INFORMA	TION ON THIS FORM	I IS PUBLIC RECORD	D UNDE	R CHAPTI	ER 610, RSMo.



BILL NUMBER: HB 869					TE: 28/2023
COMMITTEE: Veterans				·	
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO	FOR	INFORMATIO	ONAL PURPOSES
		WITNESS NAME			
REGISTERED LO	OBBYIST:				
WITNESS NAME: SUSAN GRIFFITH				HONE NUMBER: 73-424-4951	
REPRESENTING: CERTIFIED ALTER	NATIVE MEDICINE PR	OVIDERS	TI.	TLE:	
ADDRESS: 244 FAIRWAY GRE	EEN DRIVE				
CITY: O'FALLON				TATE: O	ZIP: 63368
EMAIL:		ATTENDANCE:		SUBMIT DATE: 2/28/2023	
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDE	R CHAPTI	ER 610, RSMo.



BILL NUMBER: HB 869				DATE: 2/28/2023
COMMITTEE: Veterans				
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
INDIVIDUAL:				
WITNESS NAME: TYLER MARLER D	00		PHONE NUME	BER:
BUSINESS/ORGANIZATIC	DN NAME:		TITLE:	
ADDRESS:				
CITY:			STATE:	ZIP:
EMAIL: tmarler@atsu.edu		ATTENDANCE: Written	SUBMIT [2/27/20	DATE: 123 10:03 PM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.
	-	nend alternative and natu		

have evidence of efficacy but may not be recognized universally as the preferred or standard treatment method. I do stand by the oath that a physician takes to do no harm and the side effects of such alternative or natural medicine should be elucidated to the patient.



BILL NUMBER: HB 869				DATE: 2/28/2023
COMMITTEE: Veterans				
TESTIFYING:	✓ IN SUPPORT OF	IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORG	ANIZATION:			
WITNESS NAME: WILLIAM WISNER			PHONE NUME 314-358-5	
BUSINESS/ORGANIZATIC			TITLE: EXECUTIN	/E DIRECTOR
ADDRESS: 7003 SPAVALE DF	RIVE			
CITY: HIGH RIDGE			STATE: MO	ZIP: 63049
EMAIL:		ATTENDANCE:	SUBMIT E 2/28/20	DATE: 123 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.



BILL NUMBER: HB 869				DATE: 2/28/2023
COMMITTEE: Veterans				
TESTIFYING:	IN SUPPORT OF	✓ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
	OBBYIST:			
WITNESS NAME: JEFF HOWELL			PHONE NUME 573-636-5	
REPRESENTING: MISSOURI STATE	MEDICAL ASSOCIATIO	ON	TITLE: EVP	
ADDRESS: 113 MADISON STF	REET, P.O. BOX 1028			
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65102
EMAIL: jhowell@msma.or	g	ATTENDANCE: In-Person	SUBMIT I 2/28/20	DATE: 023 8:16 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.
MSMA opposes th	e dispensation of any	Schedule 1 drug.		



BILL NUMBER: HB 869					TE: 28/2023
COMMITTEE: Veterans					
TESTIFYING:	IN SUPPORT OF	IN OPPOSITION TO	FOR INF	ORMATIC	ONAL PURPOSES
		WITNESS NAME			
INDIVIDUAL:					
WITNESS NAME: JOSHUA S. SIEGE	E		PHON	E NUMBER:	
BUSINESS/ORGANIZATIO	DN NAME:		TITLE:		
ADDRESS:			I		
CITY:			STATE	E:	ZIP:
EMAIL:		ATTENDANCE:	SU 2	JBMIT DATE: /28/2023 1	12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER	СНАРТ	ER 610, RSMo.



BILL NUMBER: HB 869			DATE: 2/28/2023
COMMITTEE: Veterans			
TESTIFYING: IN SUPPORT OF	IN OPPOSITION TO		ATIONAL PURPOSES
	WITNESS NAME		
BUSINESS/ORGANIZATION:			
WITNESS NAME: RAMON MARTINEZ		PHONE NUMB 573-316-52	
BUSINESS/ORGANIZATION NAME: MOST POLICY INITIATIVE		TITLE: PHD	
ADDRESS: 238 E HIGH ST.			
CITY: JEFFERSON CITY		STATE: MO	ZIP: 65101
EMAIL: ramon@mostpolicyinitiative.org	ATTENDANCE: In-Person	SUBMIT D 2/28/20	ATE: 23 8:06 AM
THE INFORMATION ON THIS FORM	I IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.
MOST Policy Initiative is a non partisan n			
Brief on natural medicines for trauma/pal			
we are happy to make available to the me			
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin			
I drug listing. The Controlled Substances			
can assign compounds to that heavily res			
Licensed researchers are often under hea			
As such long term and large scale efficac			
other therapeutics. However, private fund			
has streamlined their regulatory process,			
meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hall			
potential for addiction or overdose. Side			
headache, higher blood pressure, fear or			
strongest evidence for use on treatment-			
patients. The drug shows promise for use			
lacking. Data on other compounds menti			
showing efficacy in PTSD patients in a lar			
approved for the treatment adult major de (OR and WA) have legalized the use of me			
Federal Right to Try Act allows people act			
small, early trial; Religious Freedom Rest			
and ayahuasca for ceremonial purposes.			
medicinal use, personal use, or decrimina			



BILL NUMBER: HB 869			1	
				DATE: 2/28/2023
COMMITTEE: Veterans				
TESTIFYING: IN SUPPORT OF	IN OPPOSITION TO	FOR IN	FORMAT	IONAL PURPOSES
	WITNESS NAME			
BUSINESS/ORGANIZATION:				
WITNESS NAME: RAMON MARTINEZ			NE NUMBER	
BUSINESS/ORGANIZATION NAME: MOST POLICY INITIATIVE		TITLE		
ADDRESS: 238 E HIGH ST.				
CITY: JEFFERSON CITY		STAT MO	E:	ZIP: 65101
EMAIL: ramon@mostpolicyinitiative.org	ATTENDANCE: In-Person		SUBMIT DAT 2/28/2023	E: 8:14 AM
THE INFORMATION ON THIS FORM	I IS PUBLIC RECOR	D UNDER	CHAPT	TER 610, RSMo.
MOST Policy Initiative is a non profit non				
Brief on natural medicines for trauma/pall				psilocybin which
we are happy to make available to the mer				are on our
website mostpolicyInitiative.org Research	n Summary - Q: What is t	the therape	utic pote	are on our ential of
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin	n Summary - Q: What is ? First, important to unc	the therape lerstand the	utic pote e implica	are on our ential of tions of Schedule
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin ' I drug listing. The Controlled Substances	n Summary - Q: What is ? First, important to unc Act has a list of drugs ti	the therape lerstand the nat either th	utic pote e implica ne FDA, D	are on our ential of tions of Schedule DEA, or Congress
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res	n Summary - Q: What is ? First, important to unc Act has a list of drugs th strict not only access bu	the therape lerstand the nat either th t federal fu	utic pote e implica ne FDA, E nding to	are on our ential of tions of Schedule DEA, or Congress these drugs.
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea	n Summary - Q: What is ? First, important to unc Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but a	the therape lerstand the nat either th t federal fu so often ha	utic pote e implica ne FDA, E nding to nve to rai	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds.
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res	n Summary - Q: What is ? First, important to und Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but all y of these drugs is unkr	the therape lerstand the nat either th t federal fu so often ha own compa	utic pote e implica ne FDA, E nding to nve to rais ared to ro	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process,	n Summary - Q: What is ? First, important to und Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but a y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on th	the therape lerstand the nat either th t federal fu so often ha own comp s been inve ne "Breakth	utic pote e implica ne FDA, E nding to nve to rais ared to rais ared to rais rated in the rough The	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list,
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia	n Summary - Q: What is ? First, important to und Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but al y of these drugs is unkr ding (\$420 M in 2019) has putting psilocybin on th I improvement over cur	the therape lerstand the nat either th t federal fu lso often ha own comp s been inve ne "Breakth rent option	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in the rough The s, could g	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved.
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu	n Summary - Q: What is ? First, important to und Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but al y of these drugs is unkr ding (\$420 M in 2019) has putting psilocybin on th i improvement over cur ucinatory compound tha	the therape lerstand the nat either the t federal fu lso often ha own comp s been inve s been inve ne "Breakther rent options t has low p	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in the rough The s, could gotential f	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e	A Summary - Q: What is ? First, important to unc Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but al y of these drugs is unkr ding (\$420 M in 2019) has putting psilocybin on th al improvement over cur ucinatory compound that effects can include naus	the therape lerstand the nat either the t federal fu lso often ha own compa- s been inve s been inve e "Breakther rent options t has low p ea, vomitin	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in th rough Th s, could g otential f g, muscl	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness,
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficace other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or	A Summary - Q: What is ? First, important to unc Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but al y of these drugs is unkr ding (\$420 M in 2019) has putting psilocybin on th al improvement over cur ucinatory compound that effects can include naus paranoia, and reduction	the therape lerstand the nat either the t federal fu so often ha own compa- s been inve s been inve e "Breakth rent options t has low p ea, vomitin in coordina	utic pote e implica ne FDA, E nding to twe to rais ared to ro sted in th rough Th s, could g otential f g, muscl ation The	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, e drugs shows the
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or strongest evidence for use on treatment-re	A Summary - Q: What is ? First, important to unc Act has a list of drugs th strict not only access bu ivy scrutiny (DEA) but al y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on th al improvement over cur ucinatory compound that effects can include naus paranoia, and reduction resistant depression and	the therape lerstand the nat either the t federal fu so often ha own compa- s been inve as been inve as been inve as been inve t as low p ea, vomitin in coordina I anxiety, es	utic pote e implica ne FDA, E nding to twe to rais ared to ro sted in th rough Th s, could g otential f g, muscl ation The specially	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, e drugs shows the for terminally ill
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficace other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or	A Summary - Q: What is ? First, important to und Act has a list of drugs the strict not only access but by scrutiny (DEA) but all y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on the l improvement over cur ucinatory compound that effects can include naus paranoia, and reduction resistant depression and e in PTSD, but studies on	the therape lerstand the nat either th t federal fu so often ha own compa- s been inve e "Breakth rent options t has low p ea, vomitin in coordina l anxiety, es n trauma af	utic pote e implica ne FDA, E nding to ive to rais ared to ro sted in the rough Th s, could g otential f g, muscl ation The specially fected pa	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, e drugs shows the for terminally ill ttients are still
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or p strongest evidence for use on treatment-re patients. The drug shows promise for use lacking. Data on other compounds mention showing efficacy in PTSD patients in a large	A Summary - Q: What is ? First, important to und Act has a list of drugs the strict not only access but by scrutiny (DEA) but all y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on the limprovement over cur ucinatory compound that effects can include naus paranoia, and reduction resistant depression and oned in these bills, like ling oge trial. Spravato is a sy	the therape lerstand the nat either the t federal fu so often ha own compa- s been inve a "Breakther t has low p ea, vomitin in coordina I anxiety, es n trauma aff MDMA is st ynthesized	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in the rough Th s, could g otential f g, muscl ation The specially fected pa ill develo form of k	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, e drugs shows the for terminally ill htients are still oping, but is etamine FDA-
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or p strongest evidence for use on treatment-re patients. The drug shows promise for use lacking. Data on other compounds mention showing efficacy in PTSD patients in a large approved for the treatment adult major de	A Summary - Q: What is ? First, important to und Act has a list of drugs the strict not only access but vy scrutiny (DEA) but all y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on the limprovement over cur ucinatory compound that effects can include naus paranoia, and reduction resistant depression and e in PTSD, but studies or oned in these bills, like for ge trial. Spravato is a sy pressive disorder, but we	the therape lerstand the nat either the t federal fu so often ha own compa- s been inve to "Breakthe rent options t has low p ea, vomiting in coording anxiety, es trauma aff MDMA is st with high co	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in the rough The s, could g otential f g, muscl ation The specially fected pa ill develo form of k st barrie	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, e drugs shows the for terminally ill thents are still oping, but is etamine FDA- rs. Two states
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or p strongest evidence for use on treatment-re patients. The drug shows promise for use lacking. Data on other compounds mention showing efficacy in PTSD patients in a large approved for the treatment adult major de (OR and CO) have legalized the use of men	A Summary - Q: What is ? First, important to und Act has a list of drugs the strict not only access but by scrutiny (DEA) but all y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on the limprovement over cur ucinatory compound that effects can include naus paranoia, and reduction resistant depression and e in PTSD, but studies or oned in these bills, like ling trial. Spravato is a sy pressive disorder, but we dicinal psilocybin under	the therape lerstand the nat either the t federal fu so often ha own comp s been inve t been inve t "Breakthe rent options t has low p ea, vomitin in coordins t naxiety, es t trauma aff WDMA is st with high co r supervision	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in the rough The s, could g otential f g, muscl ation The specially fected pa ill develo form of k st barrie on in trea	are on our ential of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, e drugs shows the for terminally ill tients are still oping, but is etamine FDA- rs. Two states tment centers.
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or p strongest evidence for use on treatment-re patients. The drug shows promise for use lacking. Data on other compounds mention showing efficacy in PTSD patients in a large approved for the treatment adult major de (OR and CO) have legalized the use of men-	A Summary - Q: What is ? First, important to und Act has a list of drugs the strict not only access but by scrutiny (DEA) but all y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on the limprovement over cur ucinatory compound that effects can include naus paranoia, and reduction resistant depression and e in PTSD, but studies or oned in these bills, like bills ge trial. Spravato is a sy epressive disorder, but we dicinal psilocybin under cess to these compound	the therape lerstand the nat either the t federal fu so often ha own comp s been inve t been inve t "Breakthe rent options t has low p ea, vomitins in coordins a nxiety, es trauma aff WDMA is st vith high co r supervisions is if they ha	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in the rough The s, could g otential f g, muscl ation The specially fected pa ill develo form of k st barrie on in trea	are on our initial of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, drugs shows the for terminally ill tients are still oping, but is etamine FDA- rs. Two states tment centers. through at least 1
website mostpolicylnitiative.org Research psychotropic compounds like psilocybin I drug listing. The Controlled Substances can assign compounds to that heavily res Licensed researchers are often under hea As such long term and large scale efficacy other therapeutics. However, private fund has streamlined their regulatory process, meaning if the drug provides a substantia What is the data on Psilocybin?: Is a hallu potential for addiction or overdose. Side e headache, higher blood pressure, fear or p strongest evidence for use on treatment-re patients. The drug shows promise for use lacking. Data on other compounds mention showing efficacy in PTSD patients in a large approved for the treatment adult major de (OR and CO) have legalized the use of men	A Summary - Q: What is ? First, important to und Act has a list of drugs the strict not only access but by scrutiny (DEA) but all y of these drugs is unkn ding (\$420 M in 2019) has putting psilocybin on the limprovement over cur- ucinatory compound that effects can include naus paranoia, and reduction resistant depression and in PTSD, but studies or oned in these bills, like bills ge trial. Spravato is a sy pressive disorder, but we dicinal psilocybin under cost to these compound oration Act allows access	the therape lerstand the nat either the t federal fur so often ha own comp s been invert t bas low p ea, vomitin in coordina t has low p ea, vomitin in coordina t naviety, es trauma aff MDMA is st vith high coor supervision is f they ha as to certain	utic pote e implica ne FDA, E nding to ave to rais ared to ro sted in the rough The s, could g otential f g, muscl ation The specially fected pa ill develo form of k st barrie on in trea ave gone n hallucir	are on our initial of tions of Schedule DEA, or Congress these drugs. se private funds. obust data for his research. FDA herapy" list, get approved. or abuse, no e weakness, drugs shows the for terminally ill tients are still oping, but is etamine FDA- rs. Two states tment centers. through at least 1 hogens like peyote